Abstract: Methods and compositions for treating pain associated with osteoarthritis of the knee and/or hip are disclosed. In certain aspects, the subject to be treated is selected on the basis of the number of joints that exhibit osteoarthritis and/or on the basis of levels of alkaline phosphatase in the subject. In certain aspects, the subject is treated with an anti-NGF antibody such as fasinumab.

Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

Abstract: An apparatus and method for reforming a fuel include: first and second partial oxidation zones; and first and second catalytic zones containing first and second catalysts respectively. The first catalytic zone is in fluid communication with the first and second partial oxidation zones. The second catalytic zone is in fluid communication with the second partial oxidation zone. The first partial oxidation zone has at least one burner adapted to partially oxidate at least a portion of a first stage feed of the fuel with at least a portion of a first stream of an oxidant. The second partial oxidation zone has at least one other burner adapted to partially oxidate at least a portion of a second stage feed of the fuel or an other feed of an other fuel with at least a portion of a second stream of the oxidant or an other oxidant.

Abstract: The present invention relates to a method and furnace for generating straightened flames in a steam methane reformer or ethylene cracking furnace where fuel-staged burners are used. Fuel staging may be used for reducing NOx emissions. Criteria for generating straightened flames are provided. These criteria relate to oxidant conduit geometry and furnace geometry. Techniques for modifying the furnace and/or burners to achieve these criteria are also provided.